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Abstract
Non-prescriptional use of medicinal herbs among cancer patients is common around the world.
The alleged anti-cancer effects of most herbal extracts are mainly based on studies derived from in
vitro or in vivo animal experiments. The current information suggests that these herbal extracts
exert their biological effect either through cytotoxic or immunomodulatory mechanisms. One of
the active compounds responsible for the immune effects of herbal products is in the form of
complex polysaccharides known as β-glucans. β-glucans are ubiquitously found in both bacterial or
fungal cell walls and have been implicated in the initiation of anti-microbial immune response. Based
on in vitro studies, β-glucans act on several immune receptors including Dectin-1, complement
receptor (CR3) and TLR-2/6 and trigger a group of immune cells including macrophages,
neutrophils, monocytes, natural killer cells and dendritic cells. As a consequence, both innate and
adaptive response can be modulated by β-glucans and they can also enhance opsonic and non-
opsonic phagocytosis. In animal studies, after oral administration, the specific backbone 1→3 linear
β-glycosidic chain of β-glucans cannot be digested. Most β-glucans enter the proximal small
intestine and some are captured by the macrophages. They are internalized and fragmented within
the cells, then transported by the macrophages to the marrow and endothelial reticular system.
The small β-glucans fragments are eventually released by the macrophages and taken up by other
immune cells leading to various immune responses. However, β-glucans of different sizes and
branching patterns may have significantly variable immune potency. Careful selection of appropriate
β-glucans is essential if we wish to investigate the effects of β-glucans clinically. So far, no good
quality clinical trial data is available on assessing the effectiveness of purified β-glucans among cancer
patients. Future effort should direct at performing well-designed clinical trials to verify the actual
clinical efficacy of β-glucans or β-glucans containing compounds.
Introduction
A significant proportion of cancer patients have been tak-
ing complementary medical therapies while receiving
their conventional anti-cancer treatments [1-6]. Among
them, herbal extracts such as Ganoderma lucidum are one
of the most common modalities being consumed espe-
cially among Oriental [7-10]. Two mechanisms have been
proposed to be responsible for the anti-cancer action of
these herbal extracts; one is via direct cytotoxic effect and
the other is indirectly through immunomodulatory action
[11,12]. Many cytotoxic chemotherapeutic agents cur-
rently in use such as vincristine, taxol and etoposide are
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with immunomodulatory functions have mainly been
advocated by commercial sectors and most of them can be
directly purchased over the counter or the internet. Unfor-
tunately, organized efforts to investigate the actual useful-
ness of this group of herbs as well as their active
ingredients are lacking. In recent years, one of the active
ingredients responsible for the immunomodulation of
many of these herbs was found to be a form of complex
polysaccharides known as "β-D-glucan", or simply called
β-glucan [8,13]. The receptors and mechanisms of action
of β-glucans have recently been unfolded via in vitro and
in vivo animal experiments. Since β-glucans are inexpen-
sive and have good margin of safety based on historical
track records, their potential therapeutic value deserve fur-
ther investigation. We reviewed here the literature and our
experience on the in vitro and in vivo animal biological
studies of β-glucans, particularly on their immune and
anti-cancer mechanisms.
Physical and chemical properties of β-glucan
β-glucans are one of the most abundant forms of polysac-
charides found inside the cell wall of bacteria and fungus.
All β-glucans are glucose polymers linked together by a
1→ 3 linear β-glycosidic chain core and they differ from
each other by their length and branching structures [14]
(Figure 1). The branches derived from the glycosidic chain
core are highly variable and the 2 main groups of branch-
ing are 1→4 or 1→6 glycosidic chains. These branching
assignments appear to be species specific, for example, β-
glucans of fungus have 1→6 side branches whereas those
of bacteria have 1→4 side branches. The alignments of
branching follow a particular ratio and branches can arise
from branches (secondary branches). In aqueous solu-
tion, β-glucans undergo conformational change into tri-
ple helix, single helix or random coils. The immune
functions of β-glucans are apparently dependent on their
conformational complexity [15]. It has been suggested
that higher degree of structural complexity is associated
with more potent immunmodulatory and anti-cancer
effects.
For research purposes, the composition or structural
information of β-glucans can be evaluated by a variety of
methods including liquid chromatography/mass spec-
trometry (LC/MS)[16], high performance liquid chroma-
tography (HPLC)[17] and less often X-ray crystallography
[18] or atomic force microscopy [19]. However, due to the
tedious and lack of quantitative nature of most of these
technical methods, they cannot be applied routinely as a
screening tool. Other less sophisticated techniques in
studying the β-glucans contents include phenol-sulphuric
acid carbohydrate assay, aniline blue staining method and
ELISA. Because chemical modification invariably induces
changes in the natural conformation, most of these meth-
ods cannot reflect the genuine relationship between the
structure and the bioactivity. Among them, aniline blue
staining method is a relatively simple method to screen
for β-glucan because of its ability to retain the natural con-
formation of β-glucans during the staining process. It also
has a good specificity for β-glucans but its limitation is
that it can only measure the core 1→3 linear glycosidic
chain and not the branches.
Endotoxin contamination is another important issue
affecting the safety and potential biological effect of β-glu-
can. Lipopolysaccharide (LPS) is an endotoxin found
inside the Gram negative bacterial cell wall and consists of
three main parts including lipid A, core and polysaccha-
ride chain [20]. Among them, lipid A was found to be the
major component that can initiate an immune response.
LPS contamination can occur during the culture or prepa-
ration of β-glucans. Since LPS is one of the most potent
immune stimulator and its contamination can lead to
false positive results in immune tests, quantification of
LPS should be performed, which can be evaluated by
either the rabbit pyrogen test or the modified limulus
amebocyte lysate (LAL) assay with devoid factor G [21].
Pharmacodynamics & Pharmacokinetics of β-glucan
Most β-glucans are considered as non-digestible carbohy-
drates and are fermented to various degrees by the intesti-
nal microbial flora [22-24]. Therefore, it has been
speculated that their immunomodulatory properties may
be partly attributed to a microbial dependent effect. How-
ever, β-glucans in fact can directly bind to specific recep-
tors of immune cells, suggesting a microbial independent
immunomodulatory effect [25]. The pharmacodynamics
and pharmacokinetics of β-glucans have been studied in
animal and human models.
Animal Studies
Study using a suckling rat model for evaluation of the
absorption and tissues distribution of enterally adminis-
tered radioactive labeled β-glucan, it was found that the
majority of β-glucan was detected in the stomach and
duodenum 5 minutes after the administration [26]. This
amount rapidly decreased during first 30 minutes. A sig-
nificant amount of β-glucan entered the proximal intes-
tine shortly after ingestion. Its transit through the
proximal intestine decreased with time with a simultane-
ous increase in the ileum. Despite low systemic blood lev-
els (less than 0.5%), significant systemic
immunomodulating effects in terms of humoral and cel-
lular immune responses were demonstrated.
The pharmacokinetics following intravenous administra-
tion of 3 different highly purified and previously charac-
terized β-glucans were studied using carbohydrates
covalently labeled with a fluorophore on the reducing ter-Page 2 of 11
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quency and solution conformation were shown to have
an impact on the elimination half-life, volume of distribu-
tion and clearance [27].
The low systemic blood level of β-glucans after ingestion
does not reflect the full picture of the pharmacodynamics
of β-glucans and does not rule out its in vivo effects. Che-
ung-VKN et al. labeled β-glucans with fluorescein to track
their oral uptake and processing in vivo. The orally admin-
istered β-glucans were taken up by macrophages via the
Dectin-1 receptor and was subsequently transported to
the spleen, lymph nodes, and bone marrow. Within the
bone marrow, the macrophages degraded the large β-1,3-
glucans into smaller soluble β-1,3-glucan fragments.
These fragments were subsequently taken up via the com-
β-glucan is one of the key components of the fungal cell wallFi re 1
β-glucan is one of the key components of the fungal cell wall. The basic subunit of the fungal β-glucan is β-D-glucose 
linked to one another by 1→3 glycosidic chain with 1→6 glycosidic branches. The length and branches of the β-glucan from 
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These granulocytes with CR3-bound β-glucan-fluorescein
were shown to kill inactivated complement 3b (iC3b)-
opsonized tumor cells after they were recruited to a site of
complement activation such as tumor cells coated with
monoclonal antibody [28] (Figure 2). It was also shown
that intravenous administered soluble β-glucans can be
delivered directly to the CR3 on circulating granulocytes.
Furthermore, Rice PJ et al. showed that soluble β-glucans
such as laminarin and scleroglucan can be directly bound
and internalized by intestinal epithelial cells and gut asso-
ciated lymphoid tissue (GALT) cells [29]. Unlike macro-
phage, the internalization of soluble β-glucan by
intestinal epithelial cells is not Dectin-1 dependent. How-
ever, the Dectin-1 and TLR-2 are accountable for uptake of
soluble β-glucan by GALT cells. Another significant find-
ing of this study is that the absorbed β-glucans can
increase the resistance of mice to bacterial infection chal-
lenge.
Human Studies
How β-glucans mediate their effects after ingestion in
human remained to be defined. In a phase I study for the
assessment of safety and tolerability of a soluble form oral
β-glucans [30]. β-glucans of different doses (100 mg/day,
200 mg/day or 400 mg/day) were given respectively for 4
consecutive days. No drug-related adverse events were
observed. Repeated measurements of β-glucans in serum,
however, revealed no systemic absorption of the agent fol-
lowing the oral administration. Nonetheless, the immu-
noglobulin A concentration in saliva increased
significantly for the 400 mg/day arm, suggesting a sys-
temic immune effect has been elicited. One limitation of
this study is the low sensitivity of serum β-glucans deter-
mination.
In summary, based on mostly animal data, β-glucans
enter the proximal small intestine rapidly and are cap-
tured by the macrophages after oral administration. The β-
glucans are then internalized and fragmented into smaller
sized β-glucans and are carried to the marrow and
endothelial reticular system. The small β-glucans frag-
ments are then released by the macrophages and taken up
by the circulating granulocytes, monocytes and dendritic
cells. The immune response will then be elicited. How-
ever, we should interpret this information with caution as
most of the proposed mechanisms are based on in vitro
The uptake and subsequent actions of β-glucan on immune cellsFigure 2
The uptake and subsequent actions of β-glucan on immune cells. β-glucans are captured by the macrophages via the 
Dectin-1 receptor with or without TLR-2/6. The large β-glucan molecules are then internalized and fragmented into smaller 
sized β-glucan fragments within the macrophages. They are carried to the marrow and endothelial reticular system and subse-
quently released. These small β-glucan fragments are eventually taken up by the circulating granulocytes, monocytes or macro-
phages via the complement receptor (CR)-3. The immune response will then be turned on, one of the actions is the 
phagocytosis of the monoclonal antibody tagged tumor cells.Page 4 of 11
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dence for these hypothesized mechanisms of action and
pharmacokinetics occurred in human subjects at the
moment.
β-glucans as immunomodulating agent
Current data suggests that β-glucans are potent immu-
nomodulators with effects on both innate and adaptive
immunity. The ability of the innate immune system to
quickly recognize and respond to an invading pathogen is
essential for controlling infection. Dectin-1, which is a
type II transmembrane protein receptor that binds β-1,3
and β-1,6 glucans, can initiate and regulate the innate
immune response [31-33]. It recognizes β-glucans found
in the bacterial or fungal cell wall with the advantage that
β-glucans are absent in human cells. It then triggers effec-
tive immune responses including phagocytosis and proin-
flammatory factors production, leading to the elimination
of infectious agents [34,35]. Dectin-1 is expressed on cells
responsible for innate immune response and has been
found in macrophages, neutrophils, and dendritic cells
[36]. The Dectin-1 cytoplasmic tail contains an immu-
noreceptor tyrosine based activation motif (ITAM) that
signals through the tyrosine kinase in collaboration with
Toll-like receptors 2 and 6 (TLR-2/6) [34,37,38]. The
entire signaling pathway downstream to dectin-1 activa-
tion has not yet been fully mapped out but several signal-
ing molecules have been reported to be involved. They are
NF-κB (through Syk-mediate pathway), signaling adaptor
protein CARD9 and nuclear factor of activated T cells
(NFAT) [39-41] (Fig. 3). This will eventually lead to the
release of cytokines including interleukin (IL)-12, IL-6,
tumor necrosis factor (TNF)-α, and IL-10. Some of these
cytokines may play important role in the cancer therapy.
On the other hand, the dendritic cell-specific ICAM-3-
grabbing non-integrin homolog, SIGN-related 1
(SIGNR1) is another major mannose receptor on macro-
phages that cooperates with the Dectin-1 in non-opsonic
recognition of β-glucans for phagocytosis [42] (Fig 3).
Furthermore, it was found that blocking of TLR-4 can
inhibit the production of IL-12 p40 and IL-10 induced by
purified Ganoderma glucans (PS-G), suggesting a vital
role of TLR-4 signaling in glucan induced dendritic cells
maturation. Such effect is also operated via the augmenta-
tion of the IκB kinase, NF-κB activity and MAPK phospho-
rylation [43]. One additional point to note is that those
studies implied the interaction between β-glucans and
TLR all used non-purified β-glucans, therefore the actual
involvement of pure β-glucans and TLR remains to be
proven.
Other possible receptors and signaling pathways induced
by β-glucans are less definite at the moment. For example,
lentinan, a form of mushroom derived β-glucans, has
been found to bind to scavenger receptor found on the
surface of myeloid cells and triggers phosphatidylinositol-
3 kinase (PI3K), Akt kinase and p38 mitogen-activated
protein kinase (MAPK) signaling pathway [44](Fig. 3).
But no specific β-glucans scavenger receptor has been
identified so far. Candida albicans derived β-glucans but
not other forms of pathogenic fungal β-glucans can bind
to LacCer receptor and activate the PI-3K pathway in con-
trolling the neutrophil migration [45] (Fig. 3), but such
activation pathway may involve other molecules found in
the Candida derived β-glucans.
We found that β-glucans can induce human peripheral
blood mononuclear cells proliferation [46]. It can also
enhance phenotypic and functional maturation of mono-
cyte derived dendritic cells with significant IL-12 and IL-
10 production. Similar findings were found by Lin et al.
using PS-G, in addition, treatment of dendritic cells with
PS-G resulted in enhanced T cell-stimulatory capacity and
increased T cell secretion of interferon-γ and IL-10
[43,47]. This action is at least mediated in part through
the Dectin-1 receptor. The potency of such immunomod-
ulating effects differs among β-glucans and purified
polysaccharides of different size and branching complex-
ity. In general, bigger size and more complex β-glucans
such as those derived from Ganoderma lucidum have
higher immunomodulating potency.
The adaptive immune system functions through the com-
bined action of antigen-presenting cells and T cells. Spe-
cifically, class I major histocompatibility complex (MHC-
I) antigen presentation to CD8(+) cytotoxic T cells is lim-
ited to proteosome-generated peptides from intracellular
pathogens. On the other hand, the class II MHC (MHC-II)
endocytic pathway presents only proteolytic peptides
from extracellular pathogens to CD4(+) T helper cells.
Carbohydrates have been previously thought to stimulate
immune responses independently of T cells [48]. How-
ever, zwitterionic polysaccharides (polysaccharides that
carry both positive and negative charges) such as β-glu-
cans can activate CD4(+) T cells through the MHC-II
endocytic pathway [49]. β-glucans are processed to low
molecular weight carbohydrates by a nitric oxide-medi-
ated mechanism. These carbohydrates will then bind to
MHC-II inside antigen-presenting cells such as dendritic
cells for presentation to T helper cells. Initial data sug-
gested that it subsequently leads to Th-1 response, but
there are conflicting data related to this aspect. In our in
vitro data, β-glucans do not tend to polarize T cells into
either Th-1, Th-2 or regulatory T cells [46]. However,
recent publications suggested β-glucans such as zymosan
may induce T-cells into T-reg cells in a NOD mice model
[50]. Therefore, whether β-glucans can induce important
immunologic responses through T cell activation remain
to be further investigated.Page 5 of 11
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Immune activation induced by β-glucansFigure 3
Immune activation induced by β-glucans. β-glucans can act on a variety of membrane receptors found on the immune 
cells. It may act singly or in combine with other ligands. Various signaling pathway are activated and their respective simplified 
downstream signaling molecules are shown. The reactors cells include monocytes, macrophages, dendritic cells, natural killer 
cells and neutrophils. Their corresponding surface receptors are listed. The immunomodulatory functions induced by β-glucans 
involve both innate and adaptive immune response. β-glucans also enhance opsonic and non-opsonic phagocytosis and trigger a 
cascade of cytokines release, such as tumor necrosis factor(TNF)-α and various types of interleukins (ILs).
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the activated complement receptor 3 (CR3, also known as
CD11b/CD18), which is found on natural killer (NK)
cells, neutrophils, and lymphocytes. This pathway is
responsible for opsonic recognition of β-glucans leading
to phagocytosis and reactor cells lysis. β-glucans bind to
the lectin domain of CR3 and prime it for binding to inac-
tivated complement 3b (iC3b) on the surface of reactor
cells. The reactor cells can be of any cell type including
cancer cells tagged with monoclonal antibody and coated
with iC3b. The β-glucans-activated circulating cells such
as the CR3 containing neutrophils will then trigger cell
lysis on iC3b-coated tumor cells [28]. Similarly, majority
of the human NK cells express CR3 and it was shown that
opsonization of NK cells coated with iC3b leads to an
increase in the lysis of the target. The beta chain of the
CR3 molecule (CD18) rather than the alpha chain
(CD11b) is responsible to the β-glucan binding [51,52].
This concept was supported by in vivo study demonstrat-
ing barley β-1,3;1,4-glucan given orally can potentiate the
activity of an antitumor monoclonal antibody (anti-gan-
glioside-2 or "3F8"), leading to enhanced tumor regres-
sion and survival on a human neuroblastoma xenografts
mouse model [53]. 3F8 plus β-glucan was shown to pro-
duce near-complete tumor regression or disease stabiliza-
tion whereas 3F8 or β-glucan alone showed no significant
effect. The median survival of the 3F8 plus β-glucan group
was 5.5-fold higher than that of the control groups, and
up to 47% of the mice remained progression free in con-
trast to <3% of controls at the end of the study period. No
toxicities were noted in all mice treated with β-glucan,
3F8, or 3F8 plus β-glucan.
A similar xenograft model was adopted subsequently for
investigating various targeted tumor antigens and tumor
types. It was found that β-glucan exerts similar anti-tumor
effects irrespective of antigens (GD2, GD3, CD20, epider-
mal growth factor-receptor, and HER-2) or human tumor
types (neuroblastoma, melanoma, lymphoma, epider-
moid carcinoma, and breast carcinoma) or tumor sites
(subcutaneous versus systemic). The effect was correlated
with the molecular size of the β-1,3;1,4-glucan [53,54].
Furthermore, 2 other receptors known as scavenger [55]
and lactosylceramide [56,57] also bind β-glucans and can
elicit a range of responses. β-glucans can enhance endo-
toxin clearance via scavenger receptors by decreasing TNF
production leading to improved survival in rats subjected
to Escherichia coli sepsis [58]. On the other hand, β-glu-
cans binding to lactosylceramide receptor can enhance
myeloid progenitor proliferation and neutrophil oxida-
tive burst response, leading to an increase in leukocyte
anti-microbial activity. It is also associated with the activa-
tion of NF-κB in human neutrophils [59]. Again in other
studies, structurally different β-glucans appear to have dif-
ferent affinity toward these receptors. For example, only
high molecular weight β-glucans can effectively bind to
the lactosylceramide receptor. Therefore, markedly differ-
ent host responses induced by different β-glucans are
expected.
In summary, β-glucans act on a diversity of immune
related receptors in particularly Dectin-1 and CR3, and
can trigger a wide spectrum of immune responses. The tar-
geted immune cells of β-glucans include macrophages,
neutrophils, monocytes, NK cells and dendritic cells (Fig-
ure 3). The immunomodulatory functions induced by β-
glucans involve both innate and adaptive immune
response. β-glucans also enhance opsonic and non-
opsonic phagocytosis. Whether β-glucans polarize the T
cells subset towards a particular direction remains to be
explored.
Anti-cancer effects of β-glucans
It is becoming clear that β-glucans themselves have no
direct cytotoxic effects. Studies implicating the cytotoxic
effects of β-glucans were either from studies using crude
extracts of β-glucan containing herbs or the use of β-glu-
can primed monocytes. For β-glucan containing herbs like
Ganoderma lucidum (Lingzhi), there are other active com-
ponents such as ganoderic acid from its mycelium [60]
and triterpenes from its spore [61-63], which have all
been shown to have direct anti-cancer effects independ-
ently. We did not find any direct cytotoxic effects of β-glu-
cans on a panel of common cancer cell lines tested
including carcinoma, sarcoma, and blastoma. β-glucans
also did not trigger any apoptotic pathways and had no
direct effect on the telomerase and telomeric length of the
cancer cells (unpublished data). In contrast, it stimulated
the proliferation of monocytic lineage leukemic cells in-
vitro and can facilitate the maturation of dendritic cells
derived from leukaemic cells [64]. Hence, whether it is
beneficial to apply β-glucans on leukemic patients
remains controversial and has to be considered with cau-
tion.
In the English literature, there are no clinical trials that
directly assessed the anti-cancer effects of purified β-glu-
cans in cancer patients. Most studies were assessing the
toxicity profile or underlying immune changes of the can-
cer patients without addressing on the change of cancer
status. In addition, most of the related studies used either
crude herbal extracts or a fraction of the extracts instead of
purified β-glucans. Therefore, it is difficult to identify
whether the actual effects were related to β-glucans or
other confounding chemicals found in the mixture.
In a prospective clinical trial of short term immune effects
of oral β-glucan in patients with advanced breast cancer,Page 7 of 11
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pared with 16 healthy females control [65]. Oral β-
1,3;1,6-glucan was taken daily. Blood samples were recol-
lected on the day 0 and 15. It was found that despite a rel-
atively low initial white cell count, oral β-glucan can
stimulate proliferation and activation of peripheral blood
monocytes in patients with advanced breast cancer.
Whether that can be translated into clinical benefit
remains unanswered.
Clinical trials on anti-cancer effects of natural products 
with β-glucan
Many edible fungi particularly in the mushroom species
yield immunogenic substances with potential anticancer
activity [66]. β-glucans are one of the common active
components (Table 1). In limited clinical trials on human
cancers, most were well tolerated. Among them, lentinan
derived from Lentinus edodes is a form of β-glucans [67].
Since it has poor enteric absorption, intrapleural, intra-
peritoneal [68] or intravenous routes had been adopted in
clinical trials which showed some clinical benefit when
used as an adjuvant to chemotherapy [69]. Schizophyllan
(SPG) or sizofiran is another β-glucan derived from Schiz-
ophyllan commune. Its triple helical complex β-glucans
structure prevents it from adequate oral absorption so an
intratumoral route or injection to regional lymph nodes
had been adopted [70,71]. In a randomized trial, SPG
combined with conventional chemotherapy improved
the long term survival rate of patients with ovarian cancer
[72]. But whether the prolonged survival can subse-
quently led to a better cure rate remain unanswered.
Maitake D-Fraction extracted from Grifola frondosa
(Maitake mushroom) was found to decrease the size of
the lung, liver and breast tumors in >60% of patients
when it was combined with chemotherapy in a 2 arms
control study comparing with chemotherapy alone [73].
The effects were less obvious with leukemia, stomach and
brain cancer patients [74]. But the validity of the clinical
study was subsequently questioned by another independ-
ent observer [75]. Two proteoglycans from Coriolus versi-
color (Yun Zhi) – PSK (Polysaccharide-K) and PSP
(Polysaccharopeptide) – are among the most extensively
studied β-glucan containing herbs with clinical trials
information. However, both PSK and PSP are protein-
bound polysaccharides, so their actions are not necessary
directly equivalent to pure β-glucans [76]. In a series of tri-
als from Japan and China, PSK and PSP were well toler-
ated without significant side effects [66,77-81]. They also
prolonged the survival of some patients with carcinoma
and non-lymphoid leukemia.
Ganoderma polysaccharides are β-glucans derived from
Ganoderma lucidum (Lingzhi, Reishi). While β-glucan is
the major component of the Ganoderma mycelium, it is
only a minor component in the Ganoderma spore [7].
The main active ingredient in the Ganoderma spore extract
is triterpenoid which is cytotoxic in nature. In an open-
label study on patients with advanced lung cancer, thirty-
six patients were treated with 5.4 g/day Ganoderma
polysaccharides for 12 weeks with inconclusive variable
and results on the cytokines profiles [82]. Another study
on 47 patients with advanced colorectal cancer using the
Table 1: Selected Medicinal Mushroom with β-glucans as Active Components
Herbs Common Name β-glucans structure Types of β-glucans
Lentinus edodes Shiitake mushroom β-1,3;1,6-glucan Lentinan
Schizophyllan commune Brazilian mushroom, Schizophyllan β-1,3;1,6-glucan Schizophyllan (SPG) or sizofiran
Grifola frondosa Maitake mushroom β-1,3;1,6-glucan with xylose and 
mannose
Maitake D-Fraction
Coriolus versicolor Yun Zhi Protein bound β-1,3;1,6-glucan PSP (polysaccharide peptide) PSK 
(polysaccharide-Kureha or polysaccharide-K, 
krestin)
Ganoderma lucidum Lingzhi, Reishi β-1,3;1,6-glucan Ganoderma polysaccharides, Ganopoly
Agaricus blazei Brazilian sun-mushroom, 
Himematsutake mushroom
Protein bound β-1,6-glucan Agaricus polysaccharides
Pleurotus ostreatus Oyster mushroom, píng gû β-1,3-glucan with galactose and 
mannose
Pleuran
Coprinus comatus Shaggy ink cap, lawyer's wig, or 
shaggy mane
β-1,3-glucan Coprinus polysaccharidesPage 8 of 11
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able immune response patterns [83]. These results high-
light the inconsistency of clinical outcomes in using
immune enhancing herbal extracts clinically, which may
partly be due to the impurity of the products used.
Conclusion
The intrinsic differences of the β-glucans derived from dif-
ferent sources will elicit variable immune and anti-cancer
responses. We summarized the current limitations of β-
glucan research from the literature (Table 2). The limita-
tions are further complicated by the fact that many studies
on β-glucan related herbs often used crude extracts rather
than purified compounds, therefore the confounding
effects of other chemicals cannot be totally ruled out [84].
Careful selection of appropriate β-glucan products with
good pre-test quality control is essential if we want to
understand and compare the results on how β-glucans act
on our immune system and exerting anti-cancer effects. A
possibly well-defined β-glucan standard is urgently
needed in this field for controlled experiments. So far,
there are very few clinical trial data on using purified β-
glucans for cancer patients. Future studies should aim to
obtain such information so it can assist us in applying β-
glucans rationally and effectively to our cancer patients in
the future.
Competing interests
The authors declare that there is no conflict of interests,
including conflicts of financial nature involving any phar-
maceutical or commercial company.
Authors' contributions
GCFC initiated the concept, wrote and revised the manu-
script and creating the illustrations. WKC involved in writ-
ing, coordination and revising the manuscript. DMS
involved in the preparation and revision of manuscript.
Acknowledgements
We would like to thank Dr. Anita Chan (U. Alberta) for the English editing, 
Mr. Spencer Ng for the production of the graphic figures, the Edward Sai-
Kim Hotung Paediatric Education & Research Fund, URC/CRCG Grants 
and Pau Kwong Wun Charitable Foundation for supporting the beta-glucan 
related works.
References
1. Kim MJ, Lee SD, Kim DR, Kong YH, Sohn WS, Ki SS, Kim J, Kim YC,
Han CJ, Lee JO, et al.: Use of complementary and alternative
medicine among Korean cancer patients.  The Korean journal of
internal medicine 2004, 19(4):250-256.
2. McEachrane-Gross FP, Liebschutz JM, Berlowitz D: Use of selected
complementary and alternative medicine (CAM) treat-
ments in veterans with cancer or chronic pain: a cross-sec-
tional survey.  BMC complementary and alternative medicine 2006,
6:34.
3. Inglin S, Amsler S, Arigoni F, Burton-Jeangros C, Pargoux-Vallade C,
Sappino AP: [Complementary medicine use in oncology
patients].  Revue medicale suisse 2008, 4(158):1264-1266.
4. Armstrong TS, Gilbert MR: Use of complementary and alterna-
tive medical therapy by patients with primary brain tumors.
Current neurology and neuroscience reports 2008, 8(3):264-268.
5. Mueller CM, Mai PL, Bucher J, Peters JA, Loud JT, Greene MH: Com-
plementary and alternative medicine use among women at
increased genetic risk of breast and ovarian cancer.  BMC com-
plementary and alternative medicine 2008, 8:17.
6. Yang C, Chien LY, Tai CJ: Use of complementary and alterna-
tive medicine among patients with cancer receiving outpa-
tient chemotherapy in Taiwan.  J Altern Complement Med 2008,
14(4):413-416.
7. Chan WK, Lam DT, Law HK, Wong WT, Koo MW, Lau AS, Lau YL,
Chan GC: Ganoderma lucidum mycelium and spore extracts
as natural adjuvants for immunotherapy.  J Altern Complement
Med 2005, 11(6):1047-1057.
8. Chang R: Bioactive polysaccharides from traditional Chinese
medicine herbs as anticancer adjuvants.  J Altern Complement
Med 2002, 8(5):559-565.
9. Chang S, Miles P: Ganoderma lucidum – a leader of medicinal
mushrooms.  In Mushrooms: cultivation, nutritional value, medicinal
effect, and environmental impact 1st edition. CRC Press; 2004:357-373. 
10. Chan G, Mullen P, Ha S, Wong G, Lee T, YL L: Use of alternative
medical treatments in paediatric oncology patients in Hong
Kong.  Annual Scientific Meeting of the Paediactric Society of Hong Kong
1998.
11. Wasser SP: Medicinal mushrooms as a source of antitumor
and immunomodulating polysaccharides.  Appl Microbiol Bio-
technol 2002, 60(3):258-274.
12. Borchers AT, Keen CL, Gershwin ME: Mushrooms, tumors, and
immunity: an update.  Exp Biol Med (Maywood) 2004,
229(5):393-406.
13. Ooi VE, Liu F: Immunomodulation and anti-cancer activity of
polysaccharide-protein complexes.  Curr Med Chem 2000,
7(7):715-729.
14. Stone BA, Clarke AE: Chemistry and biology of (1,3)-D-glucans.
Victoria, Australia.: La Trobe University Press; 1992. 
Table 2: Summary on the Limitations of Current β-glucans Research
Current Pitfalls or Limitations in β-glucans Research
• No β-glucan control standard with specific molecular weight and branches are available. Most of the β-glucans publication used zymosan, which is 
a mixture of chitosan, β-glucans, and cell wall particles.
• Most of the β-glucan containing herbal research are based on extracts rather than purified β-glucans
• No well characterization methods either qualitatively or quantitatively are currently available for assessing and comparing β-glucans from different 
sources.
• Lack of translational approach to apply knowledge of receptor and signal pathways of β-glucan to animal studies or clinical trials.
• The exact immunological actions and signaling pathway induced by β-glucan are still unclear and have to be further defined.Page 9 of 11
(page number not for citation purposes)
Journal of Hematology & Oncology 2009, 2:25 http://www.jhoonline.org/content/2/1/2515. Bohn J, BeMiller J: (1->3)-β-Glucans as biological response mod-
ifiers: a review of structure-functional activity relationships.
Carbohydrate Polymers 1995, 28(1):3-14.
16. Hanada N, Katayama T, Kunimori A, Yamashita Y, Takehara T: Four
different types of glucans synthesised by glucosyltransferases
from Streptococcus sobrinus.  Microbios 1993, 73(294):23-35.
17. Rolin DB, Pfeffer PE, Osman SF, Szwergold BS, Kappler F, Benesi AJ:
Structural studies of a phosphocholine substituted beta-
(1,3);(1,6) macrocyclic glucan from Bradyrhizobium japoni-
cum USDA 110.  Biochimica et biophysica acta 1992,
1116(3):215-225.
18. Jelsma J, Kreger DR: Ultrastructural observations on (1 leads to
3)-beta-D-glucan from fungal cell-walls.  Carbohydrate research
1975, 43(1):200-203.
19. Marszalek PE, Li H, Fernandez JM: Fingerprinting polysaccharides
with single-molecule atomic force microscopy.  Nature biotech-
nology 2001, 19(3):258-262.
20. Dixon DR, Darveau RP: Lipopolysaccharide heterogeneity:
innate host responses to bacterial modification of lipid a
structure.  J Dent Res 2005, 84(7):584-595.
21. Gaffin SL: Endotoxin determination in viscous opaque solu-
tions of iron dextran by Limulus amebocyte lysate.  Progress in
clinical and biological research 1979, 29:221-227.
22. Knudsen KE, Jensen BB, Hansen I: Digestion of polysaccharides
and other major components in the small and large intestine
of pigs fed on diets consisting of oat fractions rich in beta-D-
glucan.  Br J Nutr 1993, 70(2):537-556.
23. Ohno N, Terui T, Chiba N, Kurachi K, Adachi Y, Yadomae T: Resist-
ance of highly branched (1-->3)-beta-D-glucans to formoly-
sis.  Chem Pharm Bull (Tokyo) 1995, 43(6):1057-1060.
24. Wang H, Weening D, Jonkers E, Boer T, Stellaard F, Small AC, Pres-
ton T, Vonk RJ, Priebe MG: A curve fitting approach to estimate
the extent of fermentation of indigestible carbohydrates.  Eur
J Clin Invest 2008, 38(11):863-868.
25. Vos A, M'Rabet L, Stahl B, Boehm G, Garssen J: Immune-modula-
tory effects and potential working mechanisms of orally
applied nondigestible carbohydrates.  Crit Rev Immunol 2007,
27(2):97-140.
26. Vetvicka V, Dvorak B, Vetvickova J, Richter J, Krizan J, Sima P, Yvin
JC: Orally administered marine (1-->3)-beta-D-glucan Phy-
carine stimulates both humoral and cellular immunity.  Int J
Biol Macromol 2007, 40(4):291-298.
27. Rice PJ, Lockhart BE, Barker LA, Adams EL, Ensley HE, Williams DL:
Pharmacokinetics of fungal (1–3)-beta-D-glucans following
intravenous administration in rats.  Int Immunopharmacol 2004,
4(9):1209-1215.
28. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing
PX, Cheung NK, Ross GD: Mechanism by which orally adminis-
tered beta-1,3-glucans enhance the tumoricidal activity of
antitumor monoclonal antibodies in murine tumor models.
J Immunol 2004, 173(2):797-806.
29. Rice PJ, Adams EL, Ozment-Skelton T, Gonzalez AJ, Goldman MP,
Lockhart BE, Barker LA, Breuel KF, Deponti WK, Kalbfleisch JH, et
al.: Oral delivery and gastrointestinal absorption of soluble
glucans stimulate increased resistance to infectious chal-
lenge.  The Journal of pharmacology and experimental therapeutics 2005,
314(3):1079-1086.
30. Lehne G, Haneberg B, Gaustad P, Johansen PW, Preus H, Abraham-
sen TG: Oral administration of a new soluble branched beta-
1,3-D-glucan is well tolerated and can lead to increased sali-
vary concentrations of immunoglobulin A in healthy volun-
teers.  Clin Exp Immunol 2006, 143(1):65-69.
31. Sun L, Zhao Y: The biological role of dectin-1 in immune
response.  International reviews of immunology 2007, 26(5–
6):349-364.
32. Brown GD, Herre J, Williams DL, Willment JA, Marshall AS, Gordon
S: Dectin-1 mediates the biological effects of beta-glucans.
The Journal of experimental medicine 2003, 197(9):1119-1124.
33. Herre J, Gordon S, Brown GD: Dectin-1 and its role in the rec-
ognition of beta-glucans by macrophages.  Molecular immunology
2004, 40(12):869-876.
34. Schorey JS, Lawrence C: The pattern recognition receptor Dec-
tin-1: from fungi to mycobacteria.  Curr Drug Targets 2008,
9(2):123-129.
35. Brown GD: Dectin-1: a signalling non-TLR pattern-recogni-
tion receptor.  Nat Rev Immunol 2006, 6(1):33-43.
36. Taylor PR, Brown GD, Reid DM, Willment JA, Martinez-Pomares L,
Gordon S, Wong SY: The beta-glucan receptor, dectin-1, is
predominantly expressed on the surface of cells of the
monocyte/macrophage and neutrophil lineages.  J Immunol
2002, 169(7):3876-3882.
37. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM: Col-
laborative induction of inflammatory responses by dectin-1
and Toll-like receptor 2.  The Journal of experimental medicine 2003,
197(9):1107-1117.
38. Herre J, Marshall AS, Caron E, Edwards AD, Williams DL, Sch-
weighoffer E, Tybulewicz V, Reis e Sousa C, Gordon S, Brown GD:
Dectin-1 uses novel mechanisms for yeast phagocytosis in
macrophages.  Blood 2004, 104(13):4038-4045.
39. Goodridge HS, Simmons RM, Underhill DM: Dectin-1 stimulation
by Candida albicans yeast or zymosan triggers NFAT activa-
tion in macrophages and dendritic cells.  J Immunol 2007,
178(5):3107-3115.
40. Gross O, Gewies A, Finger K, Schafer M, Sparwasser T, Peschel C,
Forster I, Ruland J: Card9 controls a non-TLR signalling path-
way for innate anti-fungal immunity.  Nature 2006,
442(7103):651-656.
41. Rogers NC, Slack EC, Edwards AD, Nolte MA, Schulz O, Schweighof-
fer E, Williams DL, Gordon S, Tybulewicz VL, Brown GD, et al.: Syk-
dependent cytokine induction by Dectin-1 reveals a novel
pattern recognition pathway for C type lectins.  Immunity 2005,
22(4):507-517.
42. Taylor PR, Brown GD, Herre J, Williams DL, Willment JA, Gordon S:
The role of SIGNR1 and the beta-glucan receptor (dectin-1)
in the nonopsonic recognition of yeast by specific macro-
phages.  J Immunol 2004, 172(2):1157-1162.
43. Lin YL, Liang YC, Lee SS, Chiang BL: Polysaccharide purified from
Ganoderma lucidum induced activation and maturation of
human monocyte-derived dendritic cells by the NF-kappaB
and p38 mitogen-activated protein kinase pathways.  J Leukoc
Biol 2005, 78(2):533-543.
44. Rice PJ, Kelley JL, Kogan G, Ensley HE, Kalbfleisch JH, Browder IW,
Williams DL: Human monocyte scavenger receptors are pat-
tern recognition receptors for (1-->3)-beta-D-glucans.  J Leu-
koc Biol 2002, 72(1):140-146.
45. Sato T, Iwabuchi K, Nagaoka I, Adachi Y, Ohno N, Tamura H, Seyama
K, Fukuchi Y, Nakayama H, Yoshizaki F, et al.: Induction of human
neutrophil chemotaxis by Candida albicans-derived beta-1,6-
long glycoside side-chain-branched beta-glucan.  J Leukoc Biol
2006, 80(1):204-211.
46. Chan WK, Law HK, Lin ZB, Lau YL, Chan GC: Response of human
dendritic cells to different immunomodulatory polysaccha-
rides derived from mushroom and barley.  Int Immunol 2007,
19(7):891-899.
47. Lin YL, Lee SS, Hou SM, Chiang BL: Polysaccharide purified from
Ganoderma lucidum induces gene expression changes in
human dendritic cells and promotes T helper 1 immune
response in BALB/c mice.  Mol Pharmacol 2006, 70(2):637-644.
48. Bohn J, BeMiller J: (1->3)-β-Glucans as biological response mod-
ifiers: a review of structure-functional activity relationships.
Carbohydrate Polymers 1995, 28(1):3-14.
49. Cobb BA, Wang Q, Tzianabos AO, Kasper DL: Polysaccharide
processing and presentation by the MHCII pathway.  Cell
2004, 117(5):677-687.
50. Karumuthil-Melethil S, Perez N, Li R, Vasu C: Induction of innate
immune response through TLR2 and dectin 1 prevents type
1 diabetes.  J Immunol 2008, 181(12):8323-8334.
51. Klein E, Di Renzo L, Yefenof E: Contribution of CR3, CD11b/
CD18 to cytolysis by human NK cells.  Molecular immunology
1990, 27(12):1343-1347.
52. Di Renzo L, Yefenof E, Klein E: The function of human NK cells
is enhanced by beta-glucan, a ligand of CR3 (CD11b/CD18).
European journal of immunology 1991, 21(7):1755-1758.
53. Cheung NK, Modak S, Vickers A, Knuckles B: Orally administered
beta-glucans enhance anti-tumor effects of monoclonal anti-
bodies.  Cancer Immunol Immunother 2002, 51(10):557-564.
54. Modak S, Koehne G, Vickers A, O'Reilly RJ, Cheung NK: Rituximab
therapy of lymphoma is enhanced by orally administered (1-
->3),(1-->4)-D-beta-glucan.  Leuk Res 2005, 29(6):679-683.
55. Dushkin MI, Safina AF, Vereschagin EI, Schwartz Y: Carboxymeth-
ylated beta-1,3-glucan inhibits the binding and degradation
of acetylated low density lipoproteins in macrophages inPage 10 of 11
(page number not for citation purposes)
Journal of Hematology & Oncology 2009, 2:25 http://www.jhoonline.org/content/2/1/25Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
vitro and modulates their plasma clearance in vivo.  Cell Bio-
chem Funct.  1996, 14(3):209-217.
56. Zimmerman JW, Lindermuth J, Fish PA, Palace GP, Stevenson TT,
DeMong DE: A novel carbohydrate-glycosphingolipid interac-
tion between a beta-(1–3)-glucan immunomodulator, PGG-
glucan, and lactosylceramide of human leukocytes.  The Jour-
nal of biological chemistry 1998, 273(34):22014-22020.
57. Iwabuchi K, Nagaoka I: Lactosylceramide-enriched glycosphin-
golipid signaling domain mediates superoxide generation
from human neutrophils.  Blood 2002, 100(4):1454-1464.
58. Vereschagin EI, van Lambalgen AA, Dushkin MI, Schwartz YS, Polya-
kov L, Heemskerk A, Huisman E, Thijs LG, van den Bos GC: Soluble
glucan protects against endotoxin shock in the rat: the role
of the scavenger receptor.  Shock (Augusta, Ga) 1998,
9(3):193-198.
59. Wakshull E, Brunke-Reese D, Lindermuth J, Fisette L, Nathans RS,
Crowley JJ, Tufts JC, Zimmerman J, Mackin W, Adams DS: PGG-glu-
can, a soluble beta-(1,3)-glucan, enhances the oxidative
burst response, microbicidal activity, and activates an NF-
kappa B-like factor in human PMN: evidence for a gly-
cosphingolipid beta-(1,3)-glucan receptor.  Immunopharmacol-
ogy 1999, 41(2):89-107.
60. Tang W, Liu JW, Zhao WM, Wei DZ, Zhong JJ: Ganoderic acid T
from Ganoderma lucidum mycelia induces mitochondria
mediated apoptosis in lung cancer cells.  Life Sci 2006,
80(3):205-211.
61. Lin SB, Li CH, Lee SS, Kan LS: Triterpene-enriched extracts from
Ganoderma lucidum inhibit growth of hepatoma cells via
suppressing protein kinase C, activating mitogen-activated
protein kinases and G2-phase cell cycle arrest.  Life Sci 2003,
72(21):2381-2390.
62. Min BS, Gao JJ, Nakamura N, Hattori M: Triterpenes from the
spores of Ganoderma lucidum and their cytotoxicity against
meth-A and LLC tumor cells.  Chem Pharm Bull (Tokyo) 2000,
48(7):1026-1033.
63. Muller CI, Kumagai T, O'Kelly J, Seeram NP, Heber D, Koeffler HP:
Ganoderma lucidum causes apoptosis in leukemia, lym-
phoma and multiple myeloma cells.  Leukemia research 2006,
30(7):841-848.
64. Chan WKD, Cheung CC, Law HKD, Lau YLD, Chan GCD: Gano-
derma lucidum polysaccharides can induce human mono-
cytic leukemia cells into dendritic cells with immuno-
stimulatory function.  J Hematol Oncol 2008, 1(1):9.
65. Demir G, Klein HO, Mandel-Molinas N, Tuzuner N: Beta glucan
induces proliferation and activation of monocytes in periph-
eral blood of patients with advanced breast cancer.  Int Immu-
nopharmacol 2007, 7(1):113-116.
66. Kidd PM: The use of mushroom glucans and proteoglycans in
cancer treatment.  Altern Med Rev 2000, 5(1):4-27.
67. Miyakoshi H, Aoki T, Mizukoshi M: Acting mechanisms of Lenti-
nan in human – II. Enhancement of non-specific cell-medi-
ated cytotoxicity as an interferon inducer.  International journal
of immunopharmacology 1984, 6(4):373-379.
68. Kawaoka T, Yoshino S, Hazama S, Tangoku A, Oka M: [Clinical eval-
uation of intrapleural or peritoneal administration of lenti-
nan and OK-432 for malignant effusion].  Gan to kagaku ryoho
2003, 30(11):1562-1565.
69. Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K,
Kumada K: A multi-institutional prospective study of lentinan
in advanced gastric cancer patients with unresectable and
recurrent diseases: effect on prolongation of survival and
improvement of quality of life. Kanagawa Lentinan Research
Group.  Hepato-gastroenterology 1999, 46(28):2662-2668.
70. Nakano T, Oka K, Hanba K, Morita S: Intratumoral administra-
tion of sizofiran activates Langerhans cell and T-cell infiltra-
tion in cervical cancer.  Clinical immunology and immunopathology
1996, 79(1):79-86.
71. Kano Y, Kakuta H, Hashimoto J: Effect of sizofiran on regional
lymph nodes in patients with head and neck cancer.  Biotherapy
(Dordrecht, Netherlands) 1996, 9(4):257-262.
72. Inoue M, Tanaka Y, Sugita N, Yamasaki M, Yamanaka T, Minagawa J,
Nakamuro K, Tani T, Okudaira Y, Karita T, et al.: Improvement of
long-term prognosis in patients with ovarian cancers by adju-
vant sizofiran immunotherapy: a prospective randomized
controlled study.  Biotherapy (Dordrecht, Netherlands) 1993,
6(1):13-18.
73. Kodama N, Komuta K, Nanba H: Can maitake MD-fraction aid
cancer patients?  Altern Med Rev 2002, 7(3):236-239.
74. Kodama N, Komuta K, Nanba H: Effect of Maitake (Grifola fron-
dosa) D-Fraction on the activation of NK cells in cancer
patients.  J Med Food 2003, 6(4):371-377.
75. Black W: Several apparent errors surfaced on reading the
article in the June 2002 issue of Alternative Medicine Review
by Kodama et al. entitled "Can maitake MD-fraction aid can-
cer patients"?  Altern Med Rev 2002, 7(6):451.
76. Fisher M, Yang LX: Anticancer effects and mechanisms of
polysaccharide-K (PSK): implications of cancer immuno-
therapy.  Anticancer Res 2002, 22(3):1737-1754.
77. Hayakawa K, Mitsuhashi N, Saito Y, Nakayama Y, Furuta M,
Nakamoto S, Kawashima M, Niibe H: Effect of Krestin as adjuvant
treatment following radical radiotherapy in non-small cell
lung cancer patients.  Cancer Detect Prev.  1997, 21(1):71-77.
78. Sakamoto J, Nakazato H: [Evaluation of adjuvant immunochem-
otherapy in advanced gastric cancer].  Gan to kagaku ryoho 1993,
20(16):2525-2530.
79. Ohno R, Yamada K, Masaoka T, Ohshima T, Amaki I, Hirota Y,
Horikoshi N, Horiuchi A, Imai K, Kimura I, et al.: A randomized
trial of chemoimmunotherapy of acute nonlymphocytic
leukemia in adults using a protein-bound polysaccharide
preparation.  Cancer Immunol Immunother 1984, 18(3):149-154.
80. Nishiwaki Y, Furuse K, Fukuoka M, Ota M, Niitani H, Asakawa M,
Nakai H, Sakai S, Ogawa N: [A randomized controlled study of
PSK combined immuno-chemotherapy for adenocarcinoma
of the lung. The Advanced Lung Cancer Immuno-chemo-
therapy Study Group].  Gan to kagaku ryoho 1990, 17(1):131-136.
81. Go P, Chung CH: Adjuvant PSK immunotherapy in patients
with carcinoma of the nasopharynx.  The Journal of international
medical research 1989, 17(2):141-149.
82. Gao Y, Tang W, Dai X, Gao H, Chen G, Ye J, Chan E, Koh HL, Li X,
Zhou S: Effects of water-soluble Ganoderma lucidum polysac-
charides on the immune functions of patients with advanced
lung cancer.  J Med Food 2005, 8(2):159-168.
83. Chen X, Hu ZP, Yang XX, Huang M, Gao Y, Tang W, Chan SY, Dai
X, Ye J, Ho PC, et al.: Monitoring of immune responses to a
herbal immuno-modulator in patients with advanced color-
ectal cancer.  Int Immunopharmacol 2006, 6(3):499-508.
84. Chen J, Seviour R: Medicinal importance of fungal beta-(1-->3),
(1-->6)-glucans.  Mycol Res 2007, 111(Pt 6):635-652.Page 11 of 11
(page number not for citation purposes)
